Abbott Laboratories is a diversified global healthcare company operating across Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. It is a Dividend King, having raised its dividend for more than 50 consecutive years, and currently offers a yield near 2.5%. Abbott generates roughly 60% of its sales outside the United States and is the world leader in continuous glucose monitoring (CGM) through its FreeStyle Libre platform.
The $120 stock price target has become a focal point because it closely aligns with the Street's consensus estimate. According to data compiled by S&P Global, the average 12-month price target among roughly 26 to 27 analysts sits near $120, with individual estimates ranging from the low $100s to the mid-$130s. That places $120 roughly 17% above current levels, a realistic but not trivial distance, and just below the stock's 52-week high of $137.49 reached in 2025. For many investors, $120 represents the first meaningful milestone in a potential recovery from a steep pullback.
Abbott shares have been under pressure after peaking near $137 in 2025, trading near $102–$103 with a market capitalization of roughly $177 billion. The stock's trailing price-to-earnings (P/E) ratio sits around 33, though its forward P/E of approximately 17 to 18 reflects expected earnings growth. This divergence highlights a central tension: the market is pricing in a recovery that has yet to be fully confirmed by sustained top-line and bottom-line momentum.
Abbott's Medical Devices segment is the clearest growth engine. The business grew at a high-single-digit rate, led by electrophysiology, where the company's Volt pulsed field ablation (PFA) system received U.S. Food and Drug Administration approval and has begun commercialization. Diabetes Care also remains a standout, with CGM sales exceeding $7.5 billion in 2025 and adding roughly $1 billion in revenue annually for several consecutive years.
The company's completed $21 billion acquisition of EXAS, which adds the Cologuard cancer-screening franchise, expands Abbott into a high-growth diagnostics vertical. Management is targeting 6.5% to 7% organic growth for 2026 and expects the Nutrition business to return to volume-driven growth in the second half after launching several new products. If these segments deliver, earnings could support a re-rating toward the $120 mark.
Several obstacles stand in the way. The Nutrition business has faced softness in the U.S. pediatric market and broader category volume pressure. Abbott also faces litigation, including a wrongful death lawsuit tied to alleged defects in FreeStyle Libre 3 sensors, along with China volume-based procurement pricing headwinds in Diagnostics. Tariffs, currency fluctuations, and regulatory timing add further uncertainty. Finally, at roughly 33 times trailing earnings, the stock leaves limited room for error if execution or growth disappoints.
The analyst consensus remains a "Buy," with the average price target near $120 and a range spanning roughly $103 to $143. Recent activity reflects a more constructive tone: firms including TD Cowen, Citi, and BTIG have lifted targets, and Wolfe Research upgraded the stock to Outperform. However, the range is wide, and some estimates remain far below the average, underscoring that the $120 target is an expectation rather than a certainty.
From a technical analysis perspective, the $100 round-number level serves as an important psychological support, near where the stock has stabilized in recent sessions. On the upside, $120 is the key resistance level to overcome, and a sustained breakout above it would open the door toward the prior peak of $137.49. As long as the long-term downtrend from the 2025 high remains intact, the $120 zone is likely to act as a meaningful supply area.
Tickeron's AI Daily Buy/Sell Signals product uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to identify new opportunities, track existing positions, and spot shifting market trends more efficiently than manual review alone. For investors watching Abbott's path toward $120, tools like this can help contextualize short-term momentum alongside longer-term fundamentals.
A move to $120 for Abbott Laboratories is plausible but not assured. The strongest support comes from a diversified portfolio with clear growth drivers in Medical Devices, diabetes care, and the newly added cancer-screening franchise, backed by a consensus analyst target that already sits near that level. The primary risks are execution in the Nutrition business, ongoing litigation, and a valuation that already reflects optimism. Investors should monitor Medical Devices growth, Nutrition's second-half recovery, and any resolution of legal and China-related headwinds before concluding whether the $120 milestone is achievable.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ABT has been loosely correlated with MDT. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ABT jumps, then MDT could also see price increases.
| Ticker / NAME | Correlation To ABT | 1D Price Change % |
|---|---|---|
| ABT | 100% | +1.13% |
| Health Services category (240 stocks) | 2% Poorly correlated | +0.89% |
| Medical/Nursing Services category (139 stocks) | 2% Poorly correlated | +0.94% |